骨肉腫治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Osteosarcoma - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0865
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:726
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Osteosarcoma – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma – Pipeline Review, H1 2020, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 29, 10, 2, 32 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Osteosarcoma – Overview
Osteosarcoma – Therapeutics Development
Osteosarcoma – Therapeutics Assessment
Osteosarcoma – Companies Involved in Therapeutics Development
Osteosarcoma – Drug Profiles
Osteosarcoma – Dormant Projects
Osteosarcoma – Discontinued Products
Osteosarcoma – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Osteosarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Osteosarcoma - Pipeline by Aadi Bioscience Inc, H1 2020
Osteosarcoma - Pipeline by Advanced BioDesign, H1 2020
Osteosarcoma - Pipeline by Advaxis Inc, H1 2020
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
Osteosarcoma - Pipeline by Allosteros Therapeutics Inc, H1 2020
Osteosarcoma - Pipeline by Amgen Inc, H1 2020
Osteosarcoma - Dormant Projects, H1 2020
Osteosarcoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Osteosarcoma - Dormant Projects, H1 2020 (Contd..2), H1 2020
Osteosarcoma - Discontinued Products, H1 2020

【掲載企業】

Aadi Bioscience Inc
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Allosteros Therapeutics Inc
Amgen Inc
AntiCancer Inc
APEIRON Biologics AG
Arrowhead Pharmaceuticals Inc
Astex Therapeutics Ltd
AstraZeneca Plc
Atlanthera
Aurora BioPharma Inc
Autolus Therapeutics Plc
Bayer AG
BioEclipse Therapeutics Inc
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Cellestia Biotech AG
Cellmid Ltd
CorMedix Inc
CSPC Pharmaceutical Group Ltd
Curamir Therapeutics Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
ENB Therapeutics LLC
Endocyte Inc
Exelixis Inc
GlycoMimetics Inc
Hebei Senlang Biotechnology Inc Ltd
HengRui YuanZheng Bio-Technology Co Ltd
ImmunityBio Inc
Intezyne Inc
Iovance Biotherapeutics Inc
Ipsen SA
Isofol Medical AB
Iterion Therapeutics
Jiangsu Hengrui Medicine Co Ltd
Kitov Pharma Ltd
Komipharm International Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
Mateon Therapeutics Inc
MD Biosciences GmbH
Merck & Co Inc
Merck KGaA
MetCure Therapeutics LLC
Nektar Therapeutics
Nkarta Inc
Novartis AG
Oncolix Inc
Ono Pharmaceutical Co Ltd
PEEL Therapeutics Inc
Pfizer Inc
Pimera Inc
Provectus Biopharmaceuticals Inc
Scancell Holdings Plc
Shionogi & Co Ltd
Siena Biotech SpA
Singh Biotechnology LLC
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taithera Inc
Teijin Pharma Ltd
Transtarget Inc
United Therapeutics Corp
Vaccinex Inc
VCN Biosciences SL
Veana Therapeutics LLC
Y-mAbs Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨肉腫治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆